Reprogramming of Melanoma Tumor-Infiltrating Lymphocytes to Induced Pluripotent Stem Cells by Saito, Hidehito et al.
TitleReprogramming of Melanoma Tumor-Infiltrating Lymphocytesto Induced Pluripotent Stem Cells
Author(s)Saito, Hidehito; Okita, Keisuke; Fusaki, Noemi; Sabel, MichaelS.; Chang, Alfred E.; Ito, Fumito




© 2016 Hidehito Saito et al. This is an open access article
distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction





Reprogramming of Melanoma Tumor-Infiltrating Lymphocytes
to Induced Pluripotent Stem Cells
Hidehito Saito,1 Keisuke Okita,2 Noemi Fusaki,3,4 Michael S. Sabel,1
Alfred E. Chang,1 and Fumito Ito1,5
1Department of Surgery, University of Michigan, 1500 E Medical Center Drive, 3410 CC, Ann Arbor, MI 48109-5932, USA
2Center for iPS Cell Research and Application, Kyoto, Japan
3Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan
4DNAVEC Corporation, Tsukuba, Ibaraki, Japan
5Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI 48109-2200, USA
Correspondence should be addressed to Fumito Ito; oarsman92@gmail.com
Received 11 June 2015; Revised 1 October 2015; Accepted 1 October 2015
Academic Editor: Ghasem Hosseini Salekdeh
Copyright © 2016 Hidehito Saito et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Induced pluripotent stem cells (iPSCs) derived from somatic cells of patients hold great promise for autologous cell therapies. One
of the possible applications of iPSCs is to use them as a cell source for producing autologous lymphocytes for cell-based therapy
against cancer. Tumor-infiltrating lymphocytes (TILs) that express programmed cell death protein-1 (PD-1) are tumor-reactive T
cells, and adoptive cell therapy with autologous TILs has been found to achieve durable complete response in selected patients
with metastatic melanoma. Here, we describe the derivation of human iPSCs from melanoma TILs expressing high level of PD-
1 by Sendai virus-mediated transduction of the four transcription factors, OCT3/4, SOX2, KLF4, and c-MYC. TIL-derived iPSCs
display embryonic stem cell-like morphology, have normal karyotype, express stem cell-specific surface antigens and pluripotency-
associated transcription factors, and have the capacity to differentiate in vitro and in vivo. A wide variety of T cell receptor
gene rearrangement patterns in TIL-derived iPSCs confirmed the heterogeneity of T cells infiltrating melanomas. The ability to
reprogram TILs containing patient-specific tumor-reactive repertoire might allow the generation of patient- and tumor-specific
polyclonal T cells for cancer immunotherapy.
1. Introduction
A groundbreaking discovery showing that differentiated
somatic cells can be reprogrammed by transiently overex-
pressing a defined set of transcription factors offers the
opportunity to obtain patient-specific somatic cells for poten-
tial therapeutic applications [1–4].These reprogrammed cells,
referred to as induced pluripotent stem cells (iPSCs), can be
generated from mature peripheral blood T cells [5–8]. T cell
derived iPSCs can redifferentiate into functional CD8+ T cells
harboring long telomeres and increased proliferative capacity
[9, 10]. These “rejuvenated human T cells” exhibit T cell
receptor (TCR) gene rearrangement patterns identical to the
parental T cells, fromwhich the iPSC clones were established,
and antigen-specific killing effector functions in vitro [9–11].
Moreover, the iPSCs engineered to express TCR of known
antigen specificity can differentiate to antigen-specific T cells,
promote cancer immunosurveillance, andmediate antitumor
immunity in vivo [12, 13]. These findings suggest possible
applications of iPSCs for use as a cell source for producing
lymphocytes for cell-based therapy against cancer.
Adoptive cell therapy with autologous tumor-infiltrating
lymphocytes (TILs) has emerged as one of the most effective
treatments for patients with metastatic melanoma. A major
limitation of this approach is poor survival of T cells in
vivo following infusion. The majority of TILs are terminally
differentiated effector T cells that express high levels of
immunoinhibitory receptors such as programmed cell death
protein-1 (PD-1), indicative of the “exhausted phenotype” and
functional impairment [14–16]. Current clinical protocols
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for adoptive T cell therapy stipulate that differentiated T
cells require further stimulation in order to obtain large
numbers of T cells. This results in generation of terminally
differentiated CD8+ T cells that exhibit decreased antitu-
mor efficacy in vivo due to their diminished capacity to
maintain effector function after infusion compared with
less-differentiated CD8+ T cells [17–23]. This limitation of
adoptive T cell therapy can be overcome by using iPSCs
that self-renew, maintain pluripotency [1–4], and provide an
unlimited source of autologous polyclonal T cells for treating
heterogeneous tumors. However, the differentiation status
of the donor cell is known to influence the efficiency of
embryonic cell (ESC) derivation as well as iPSC generation
[24, 25]. Hence, the feasibility of reprogramming terminally
differentiated and exhausted TILs remains unknown.
Here, we report successful generation of human iPSCs
from terminally differentiated melanoma TILs that express
high levels of PD-1 by Sendai virus- (SeV-) mediated trans-
duction of the four transcription factors OCT3/4, SOX2,
KLF4, and c-MYC. All of the iPSCs generated from TIL
culture using SeV reprogramming system have TCR rear-
ranged genes indicating that they are derived from mature T
cells. Detection of a wide variety of TCR gene rearrangement
patterns in TIL-iPSCs is indicative of heterogeneous T cell
populations in melanoma TILs.
2. Materials and Methods
2.1. Ethics Statement. The study was approved by the Insti-
tutional Review Board (IRB) of the University of Michigan
(protocol number HUM00054459) and the Human Pluripo-
tent Stem Cell Research Oversight (HPSCRO) Commit-
tee (protocol number 1055) and has been performed in
accordance with the ethical standards of the responsible
committee on human experimentation and with the Helsinki
Declaration. An IRB-approved written informed consent was
obtained from all patients for being included in the study.
All animal care and procedures were in accordance with
institutional policies for animal health and well-being and
approved by the University Committee on Use and Care
of Animals (UCUCA) at the University of Michigan under
protocol number PRO00005921. Mice were euthanized using
CO
2
and cervical dislocation according to the University of
Michigan UCUCA guidelines.
2.2. Patient Cell Samples. Patients were eligible for this study
if they were 18 years of age or older and were undergoing
resection of metastasis and/or regional lymph node dissec-
tion for clinically evident regional or distant metastases of
melanoma. Patients with an immunosuppressive disorder or
an autoimmune disorder or patients receiving treatment with
immunosuppressive drugs for melanoma within 3 months
prior to entry into the study were excluded.
After written informed consent, an up to 30mL sample
of venous blood was collected in EDTA tubes (BD Bio-
sciences) from the patients. Peripheral blood mononuclear
cells (PBMCs) were isolated using Ficoll-Paque (GE Health-
care Life Sciences) density-gradient centrifugation. Freshly
resected tumors were sent from the surgery suite to the
tissue procurement core in sterile containers. The tumor
material not required for histopathologic diagnosis was
placed in collecting medium, RPMI 1640 supplemented with
200𝜇g/mL gentamicin, 5𝜇g/mL ciprofloxacin, 20𝜇g/mL
metronidazole, 100 U/mL penicillin, 50 𝜇g/mL streptomycin,
25 𝜇g/mL vancomycin, and 2.5 𝜇g/mL fungizone (all from
Life Technologies). Under sterile conditions, tumors were
dissected away from adjacent normal tissue and stroma.
2.3.Mice. Severe combined immunodeficient femalemice 6–
8 weeks old (CbySmn.CB17-Prkdcscid/J SCID) were obtained
from Jackson Laboratory.Miceweremaintained in pathogen-
free barrier conditions.
2.4. Generating TIL Cultures. Single-cell suspensions were
obtained by mechanical dispersion consisting of two 30min
incubations of 2.5 g minced melanoma tumor at 37∘C and
5% CO
2
in 5mL RPMI 1640 (Life technologies) and tumor
dissociation kit (Miltenyi Biotec) in C Tubes (Miltenyi
Biotec) interspersed with three mechanical dispersions on a
GentleMACS dissociator (Miltenyi Biotec). The tumor cell
suspensions were then filtered through a cell strainer (75𝜇m,
BD Biosciences). TILs and tumor cells were isolated with a
two-step density-gradient centrifugation [26]. In brief, tumor
suspension in RPMI was layered onto a two-step gradient
with a lower step of 100% Ficoll and a middle step of
75% Ficoll and 25% complete medium. After 45 minutes’
centrifugation at 400 g, the interfaces were collected. The
lower, TIL-enriched fraction was cultured in 24-well plates
in 2mL T cell media containing IMDM supplemented with
6,000 IU/mL recombinant human (rh) IL-2 (Aldesleukin,
Prometheus Laboratories Inc.), 10% human serum, 2mmol/L
l-glutamine, 100U/mL penicillin, 100𝜇g/mL streptomycin,
500𝜇g/mL gentamicin, and 55 𝜇M 2-mercaptoethanol (all
from Life Technologies) or collected for flow cytometric
analysis. Half of the medium was changed on day 5 after
culture initiation and every 2-3 days thereafter. TILswere split
1 : 2, doubling the number of wells when reaching confluence.
TILs were cryopreserved after expansion in 10% DMSO in
human serum.
2.5. Generation of iPSCs from Melanoma TILs. After clear-
ance of adherent cells and aweek in log phase expansion (days
21 to 28 after initiation of cultures), TILs were activated with
anti-CD3/CD28 (BD Biosciences) and rhIL-2 (6,000 IU/mL)
for 5 days. Then, TILs were reactivated with anti-CD3/CD28
in reprogramming media, X-VIVO 15 medium (Lonza) con-
taining 5% FBS, 20mM HEPES, 2mM L-glutamine, and
10U/mL of penicillin, 100 𝜇g/mL of streptomycin (all from
Life Technologies), 10mM N-acetylcysteine (Cumberland
pharmaceuticals), and 60 IU/mL rhIL-2 for 24 hours in 24-
well plate at 1 × 105 cells/well. Then, TILs were infected
with SeV vectors that individually carried each of OCT3/4,
SOX2, KLF4, and c-MYC at various multiplicity of infection
(MOI). In some experiments, TILs were infected with SeV
encoding green fluorescent protein (SeV-GFP) to determine
transduction efficiently. After 24 hours of infection, the cells
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Figure 1: Freshly isolated CD8+ tumor-infiltrating lymphocytes (TILs) showed distinct phenotypical difference compared with CD8+
peripheral blood T cells (PBTCs). Phenotypic characterization of freshly isolated CD8+ T cells in TILs and PBTCs from patient (A) and
patient (B). Expression of CCR7 and CD45RO (a) and PD-1, LAG-3, and TIM-3 (b) in CD8-gated live cells in TILs and PBTCs are shown.
Number indicates the percentage of cells shown in each quadrant (a) or indicated gated regions (b).
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Figure 2: Generation of iPSCs from melanoma tumor-infiltrating lymphocytes. (a) Time schedule outlining expansion, activation, and
reprogramming of TILs to generate iPSCs. (b) Morphologies of TILs when they started to expand 2-3 weeks after initiation of culture. (c)
Efficient GFP introduction by Sendai virus (SeV) in TILs transfected at a MOI of 20. (d) Typical ESC-like iPSC colonies on day 21 after SeV
infection. (e) Examples of 6-well plate containing SeV-reprogrammed iPSC clones stained for alkaline phosphatase (ALP), showing numerous
ALP-positive colonies. (f) Cytogenetic analysis was performed on twenty G-banded metaphase cells from one of TIL-derived iPSCs (TIL-
iPSCs). All twenty cells demonstrated a normal karyotype. (g) Immunofluorescence staining for pluripotency and surface markers (SSEA3,
SSEA4, TRA-1-81, TRA-1-60, and OCT3/4) in iPSCs derived from melanoma TILs. Scale bars represent 100 𝜇m. (h) RT-PCR analysis for the
human ES cell marker genes NANOG, OCT3/4, SOX2, KLF4, and c-MYC in TIL-iPSCs and ESCs (H1). (i) Scatter plots comparing the global
gene expression profiles of TIL-iPSCs and ESCs and TIL-iPSCs and TILs. (j) Immunofluorescence staining for SOX17 (endodermal marker),
𝛽III tubulin (ectodermal marker), and 𝛼SMA (mesodermal marker) in TIL-iPSC-derived differentiated cell. Nuclei were counterstained with
DAPI. Scale bars represent 100 𝜇m. (k) Hematoxylin and eosin-stained representative teratoma sections of TIL-iPSC clones from patients (A)
and (B) (6 weeks after injection into NOD/SCID mice).
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Figure 3: A wide variety of TCR-𝛽 gene arrangement patterns in TIL-iPSCs. Characterization of the TCR-𝛽 gene arrangement in TIL-iPSCs
from patients (A) and (B) by capillary electrophoresis. The green line is derived from the band for the J𝛽1 gene, and blue line is derived from
the band for the J𝛽2 gene.
were collected and transferred to a 10 cm dish that contained
mitomycin C-inactivated SNL feeder cells (Cell Biolabs, Inc.)
in hESC media which consisted of Primate ES Cell Medium
(Reprocell) and 4 ng/mLbasic fibroblast growth factor (bFGF,
Life technologies). The hESC medium was changed every
other day until the colonies were picked. Then, the hESC
culture medium was changed every day and the cells were
passaged using 1mg/mL collagenase IV every 5-6 days.
H1-ESCs (WiCell) were used as controls for characterizing
pluripotency of generated iPSCs.
2.6. Flow Cytometry. The following mAbs specific for
human antigens and appropriate isotype controls were used:
from BD Biosciences, allophycocyanin-Cy7-conjugated anti-
CD8 (RPA-T8), PE anti-CD4 (RPA-T4), PerCP anti-TIM-
3 (F38-2E2), PE/Cy7 anti-LAG-3 (3DS223H), Alexa Fluor
anti-CD45RO (UCHL1), and allophycocyanin anti-CCR7
(150503); and from eBioscience, FITC anti-PD-1 (J105). Cells
were resuspended in staining buffer (PBS containing 2% FBS)
and were stained with mAb against surface Ags for 30min at
4∘C in the dark. Acquisition of at least 10,000 events was done
on LSR II flow cytometer (BD Biosciences). Cell aggregates
and dead cells were excluded by forward and side scatter and
with DAPI staining for unfixed cells. Flow cytometry analysis
was carried out with FlowJo version 10.0.7 software (Tree Star,
Ashland, OR), gating based on isotype control Ab staining,
and the number in each gate represents the percentage of
cells.
2.7. Alkaline Phosphatase (ALP) and Immunofluorescence
Staining of iPSCs. ALP staining was performed with the
ALP substrate (Sigma) after fixation with 4% paraformalde-
hyde. Immunofluorescence staining was performed using
the following primary antibodies: anti-OCT 3/4 (sc-5279,
Santa cruz), anti-SSEA3 (MAB4303, Millipore), anti-SSEA4
(MAB4304, Millipore), anti-TRA-1-60 (MAB4360, Milli-
pore), and anti-TRA-1-81 (MAB4381, Millipore). The fluores-
cence signals were detected using a conventional fluorescence
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laser microscope equipped with a color charge-coupled
device (CCD) camera. The secondary antibodies used were
anti-mouse IgG and IgM or anti-rat IgM conjugated with
Alexa Fluor 488 (Jackson Immunoresearch).
2.8. Gene Expression Analysis by Reverse Transcription-
Polymerase Chain Reaction (RT-PCR). Total RNA samples
were isolated with TRIZOL reagent (Life Technologies)
from iPSCs and H1-ESCs and purified, according to the
manufacturer’s instructions. One microgram total RNA was
used for cDNA synthesis by RT-PCR with SuperScript
III Reverse Transcriptase (Life Technologies) and random
primer, according to the manufacturer’s instructions. cDNA
was amplified by PCR with Platinum Taq DNA Polymerase
(Life Technologies) and various sets of primers shown
in Table S1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2016/8394960.
2.9. Global Gene Expression Analysis. To compare tran-
scriptomes of ESCs and iPSCs, microarray analysis was
performed. RNA sample processing, probing to the human
gene 2.1 ST array platform (Affymetrix), and data analy-
sis were performed by the University of Michigan DNA
Sequencing Core Microarray Facility. Normalized expres-
sion by robust multiple-array averages was plotted using
the heatmap.2 function from the g-plots package in R
(http://www.r-project.org) using default parameters. The
euclidean distance dissimilarity matrix and complete linkage
method were used to generate the dendrogram.
2.10. In VitroDifferentiation of iPSCs. For the embryoid body
(EB) formation, iPSCs were harvested by collagenase IV and
transferred to ultralow attachment plates in hESC medium
without bFGF. After 8 days, aggregated cells were plated onto
gelatin-coated dishes for another 8 days. The cells were fixed
with PBS containing 4% paraformaldehyde for 15 minutes
at room temperature. Immunostaining was performed as
described above. The primary antibodies used were an anti-
Sox17 antibody (1 : 200, R&D Systems), anti-SMA antibody
(1 : 500, 1A4, DAKO), and anti-𝛽III tubulin (1 : 1000, TUJ1,
Covance). The secondary antibodies used were Alexa Fluor
488-conjugated donkey anti-Goat IgG (1 : 500, Life Tech-
nologies) for Sox17 and Alexa Fluor 488-conjugated donkey
anti-mouse IgG (1 : 500, Life Technologies) for SMA and
𝛽III tubulin. DAPI (Molecular Probes) was used for nuclear
staining.
2.11. Teratoma Formation and Histological Analysis. Undif-
ferentiated TIL-derived iPS cells (1 × 106) suspended in
100 𝜇L of DMEM containing 10% FCS were injected into the
subcutaneous tissue of 6- to 8-week-old female NOD/SCID
mice. Six weeks after injection, tumors were surgically dis-
sected from the mice. Samples were fixed in PBS containing
10% paraformaldehyde and embedded in paraffin. Paraffin-
embedded samples were stained with hematoxylin and eosin
for histological analysis.
2.12. T Cell Receptor-𝛽 Chain Rearrangement Analysis.
Genomic DNA was isolated per manufacturer’s protocol
(using the Qiagen DNeasy Blood and Tissue kit) from the
TIL-iPS cell lines. TCR clonotype mapping was performed
using a kit for analyzing T cell receptor-𝛽 chain rearrange-
ments (InVivoScribe Technologies). PCR was performed
using a multiplex primer kit (InVivoScribe Technologies)
specific for a majority of clonal TCR-𝛽 chain rearrange-
ments [27]. Capillary electrophoresis and PCR product frag-
ment analysis was performed at the University of Michigan
Sequencing Core Facility (Ann Arbor, MI) using an ABI
3730 DNA analyzer. Data was analyzed using Peak Scanner
software (Applied Biosystems).
2.13. Karyotyping. Standard G-banded karyotyping was car-
ried out and interpreted byCell LineGenetics (Madison,WI).
3. Results
3.1. Melanoma TILs ContainMore Differentiated CD8+ TCells
That Express High Level of PD-1 Compared with Peripheral
Blood CD8+ T Cells. Between October 2012 and March 2013,
peripheral blood and tumor specimens were obtained from
two adult patients who underwent resection of metastatic
melanoma. We first wanted to determine the differentiation
stage of T cells in the tumor and in peripheral blood which
is a critical parameter influencing reprogramming potential
of hematopoietic cells [25]. In both patients, assessment of
T cell differentiation based on the expression of CD45RO
and CCR7 showed that the majority of CD8+ TILs were
effector memory T cells (TEM: CCR7
− CD45RO+) while
peripheral blood T cells (PBTCs) contained proportionally
more central memory T cells (TCM: CCR7
+ CD45RO+) or
stem cell memory T cells (TSCM: CCR7
+ CD45RO−) than
effector memory T cells (Figure 1(a)). This suggests freshly
isolated CD8+ TILs from tumor would be more difficult
hematopoietic cells to be reprogrammed than PBTCs based
on their differentiation stage.
Recent studies have reported that CD8+ TILs from
melanoma patients expressed high levels of inhibitory recep-
tors such as programmed cell death protein-1 (PD-1), T
cell immunoglobulin and mucin domain-3 (TIM-3), and
lymphocyte activation gene-3 (LAG-3) [14–16, 28]. Of these,
PD-1 expression inCD8+ TILs accurately identified the reper-
toire of clonally expanded tumor-reactive, mutation-specific
lymphocytes [28]. Since our goal is to generate human iPSCs
which can differentiate into patient’s tumor-reactive CD8+ T
cells for immunotherapy, wemeasured cell surface expression
of inhibitory receptors, PD-1, TIM-3, and LAG-3. Freshly
isolated CD8+ TILs from both patients contained higher fre-
quencies of CD8+ T cells that expressed inhibitory receptors
most notably PD-1 than CD8+ T cells in PBTCs (Figure 1(b)).
Taken together, TILs from two melanoma patients in the
current study contained the repertoire of clonally expanded
tumor-reactive CD8+ T cells that were further differentiated
hematopoietic cell populations than peripheral blood CD8+
T cells.
8 Stem Cells International
3.2. Generation of iPS Cells fromMelanomaTumor-Infiltrating
Lymphocytes. Generation of iPS cells from human PBTCs
was reported using Sendai virus [7, 25], lentivirus [8], or
retrovirus [5, 6] that encode reprogramming factors OCT3/4,
SOX2, KLF4, and c-MYC. Of these, the reprogramming
efficiency was much higher with SeV system (∼0.1%) com-
paredwith lentivirus or retrovirus vector (∼0.001%) [6–8, 25].
Furthermore, all iPSC clones generated by using SeV system
were derived from T cells while some iPSC clones generated
by lentivirus or retrovirus vectors were from nonlymphoid
lineages [6–8]. In addition to higher efficiency and specificity
of T cell-derived iPSCs induction, SeV reprogramming sys-
tem can provide integration-free iPSC clones which can avoid
the possibility of insertional mutagenesis and other potential
disruptions of cellular function often seen when using an
integrating viral vector system for reprogramming [29]. For
these reasons, we chose to use SeV system to generate iPSCs
from terminally differentiated TILs.
A previous report described the generation of iPSCs
from PBTCs by stimulating them twice with anti-CD3
monoclonal antibody (mAb) and IL-2 5 days apart followed
by infection with SeV vectors [7]. We initially used this
protocol to reprogram TILs immediately after they were
isolated from tumor. However, viability of the TILs was poor
upon immediate stimulation with anti-CD3/CD28 mAb and
IL-2. Therefore, we cultured TLs with IL-2 alone for 3-4
weeks before stimulation (Figure 2(a)). Once TILs started
to expand (Figure 2(b)), they were stimulated with anti-
CD3/CD28 mAb. Flow cytometric analysis of freshly isolated
PBMC and TILs and TILs after 3-4 weeks of culture with IL-
2 and stimulation showed the average percentage of CD8+ T
cells was higher in freshly isolated TILs compared to PBMCs
and gradually increased over the time. After first stimulation
with anti-CD3/CD28mAb, themajority of cultured cells were
CD8+ T cells (Supplemental Figure 1). Five days after initial
stimulationwith anti-CD3/CD28mAb, TILs were reactivated
with anti-CD3/CD28 for 24 hr and then infected with SeV
for reprogramming. First, we confirmed high transduction
efficiency using SeV that encodes green fluorescent protein
(SeV-GFP) (Figure 2(c)). To generate iPSCs from TILs, SeV
vectors that individually encoded OCT3/4, SOX2, KLF4, and
c-MYC were added to the wells at a multiplicity of infection
(MOI) of 20. Twenty-four hours after gene transduction, the
cells were replated onto SNL feeder cells in hESC medium
containing 4 ng/mL bFGF (Figure 2(a)). Colonies that were
larger and morphologically similar to hESC-like colonies
were picked up within 4 weeks of infection (Figure 2(d)).
Most of the colonies were positive for alkaline phosphatase
(ALP) (Figure 2(e)), which is a characteristic marker of stem
cells. We were able to generate ten and fifty iPSCs from
patients (A) and (B), respectively. Therefore, reprogramming
efficiency was 0.01% for patient (A) and 0.05% for patient
(B). We found the efficiency of reprogramming PBTCs was
approximately 0.1% at a MOI of 3–10 (data not shown) which
is consistent with others [7, 30]. Karyotype analysis of TIL-
derived iPSCs (TIL-iPSCs) showed that the cells have no
chromosomal abnormalities (Figure 2(f)).
To determine whether TIL-iPSCs had the characteristics
of typical hESCs, we examined stem cell marker expres-
sion. The iPSCs expressed characteristic ESC markers such
as SSEA3, SSEA4, OCT3/4, TRA-1-60, and TRA-1-81 by
immunofluorescence staining (Figure 2(g)). RT-PCR analysis
showed that the iPSCs are positive for endogenous NANOG,
OCT3/4, SOX2, KLF4, and c-MYC (Figure 2(h)). Global gene
expression analysis confirmed that TIL-iPSCs and ESCs had
similar gene expression profiles and were different from the
TILs (Figure 2(i)). To further determine the pluripotency, we
evaluated the differentiation potential of TIL-iPSCs by in vitro
differentiation and teratoma formation. The TIL-iPSCs were
differentiated into embryoid bodies (EBs) in vitro, and upreg-
ulation of marker genes for all three germ layers was detected
by immunostaining (Figure 2(j)). Consistent with this in vitro
finding, TIL-iPSCs were able to form teratomas with three
germ layers such as neural tissue, respiratory epithelium, and
cartilage upon subcutaneous injection into NOD/SCID mice
(Figure 2(k)). Taken together, the TIL-iPSCs are pluripotent
and show the molecular andmorphological characteristics of
human iPSCs.
3.3. A Wide Variety of TCR-𝛽 Gene Arrangement Patterns
in TIL-iPSCs. Retained TCR rearranged gene is a hallmark
of mature T cell-derived iPSCs and is carried through the
differentiation to T cell lineage [5–11]. Therefore, we wanted
to determine the rearrangement status of TCR-𝛽 genes of
TIL-iPSCs to confirm that these iPSCs are derived from
T cells as well as investigate TCR variability in TIL-iPSCs.
We performed fragment analysis of PCR products for the
genomic DNA of the TCR-𝛽 regions in each TIL-iPSC clone.
The rearranged TCR genes were detected in all TIL-iPSCs,
confirming that iPSCs were derived from T cells (Figure 3,
Supplemental Figure 2).We identified 7 and 18 different TCR-
𝛽 gene rearrangement patterns in TIL-iPSCs from patients
(A) and (B), respectively.
4. Discussion
In the present study, we demonstrated successful reprogram-
ming of terminally differentiatedmelanomaTILs that express
high levels of PD-1 into human iPSCs by using SeV vectors
encoding OCT3/4, SOX2, KLF4, and c-MYC.The TIL-iPSCs
expressed ESC marker genes and possessed the ability to
differentiate into three germ layers in vitro and in vivo.
Moreover, TCR gene rearrangement analysis of TIL-iPSCs
revealed that TIL-iPSCs were all derived from T cells with a
wide variety of TCR rearrangement patterns, suggesting that
heterogeneity of T cell clones is present in melanoma tumors.
Aprevious study showed that SeV reprogramming system
was highly efficient and reliable in generating iPSCs not only
from fibroblasts but also from peripheral blood by a single
transduction with lower aneuploidy rates [30]. Our findings
further extended that SeV reprogramming system was also
suitable for generating iPSCs from terminally differentiated
and exhausted TILs expressing high level of inhibitory
receptors. Timing of stimulation with anti-CD3/CD28 mAb
and infection with SeV vectors were found to be critical in
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reprogramming TILs. In contrast to peripheral blood T cells
which can be stimulated with anti-CD3 mAb and IL-2 for
reprogramming immediately after they were harvested from
a donor [7], TILs needed to be cultured for 3-4 weeks with
IL-2 alone before stimulation similar to the protocol used
clinically for adoptive T cell therapy [26, 31].
Our study demonstrated that melanoma TILs from two
patients expressed high level of PD-1, which is consistent
with reports from others [14–16]. A recent study from Gros
et al. further demonstrated expression of PD-1 on CD8+
melanomaTILs identified the repertoire of clonally expanded
tumor-reactive, mutation-specific lymphocytes and these
populations played a critical role in tumor regression after
adoptive cell therapy [28]. Our data of reprogramming TILs
expressing high level of PD-1 indicates successful generation
of iPSCs from patient-specific tumor-reactive CD8+ T cells.
However, this needs to be further confirmed by evaluating the
antitumor reactivity of TIL-iPSC-derived T cells against the
patient’s tumor cells in vitro and/or in vivo using a xenograft
model [9, 10, 13].
We found TILs displayed more differentiated phenotype
and lower reprogramming efficiency compared to peripheral
blood T cells, which is in line with prior observations that
differentiation stage has a strong impact on the efficiency of
reprogramming hematopoietic cells into iPSCs [25]. Another
possible explanation is that cells being in an exhausted
state have lower reprogramming efficiency. The difference
of PD-1 expression and reprogramming efficiency of TILs
between patients (A) and (B) might suggest cells being in an
exhausted state may have a major influence on the efficiency
of reprogramming into iPSCs. However, this possibility needs
to be further evaluated with more cases.
Recent significant progressmade in reprogramming tech-
nology might improve reprogramming efficiency for genera-
tion of TIL-iPSCs. A new SeV vector, TS12KOS, was found to
have improved efficiency of iPSC generation compared with
the conventional SeV vectors used in the current study [32,
33]. Another promising avenue for future investigation is to
combine gene transductionwith signal inhibition or chemical
compounds which was found to enhance the efficiency of
iPSC generation [34–39]. Furthermore, Rais et al. recently
reported that depletion of Mbd3 (methyl-CpG binding
domain protein 3) combined with induction of the Yamanaka
factors (OCT3/4, SOX2, KLF4, and c-MYC) significantly
enhanced reprogramming efficiency and achieved nearly
100% complete conversion of mouse embryonic fibroblasts to
pluripotency within a week [40].
In line with previous observations in PBTC-derived
iPSCs [7], our data demonstrated that all iPSCs generated
by SeV reprogramming system were derived from T cells.
While human iPSCs derived from fibroblast are capable of
producing T lymphocyte populations with a broad TCR
repertoire [41], T cell-derived iPSCs bearing rearranged TCR
genes differentiate into T lineage expressing the same TCR
from the original T cells [9–11]. This will allow rejuvenated
TILs to retain the antigen specificity after reprogramming
and redifferentiation. A wide variety of TCR rearrangement
patterns in TIL-iPSC clones suggests heterogeneity of T cell
clones in melanoma tumors. This result is in support of the
study from Yazdi et al., who used laser-capture microdis-
section to isolate different TIL clusters from melanoma and
demonstrated that many different T cell clones with different
rearrangements were detected within the same individual
[42].
Although the antitumor efficacy of TIL-iPSCs or TIL-
iPSC-derived T cells remains to be elucidated, recent findings
from several groups suggest therapeutic potential of iPSC-
derived T cells. Vizcardo et al. reported successful repro-
gramming of a T cell clone recognizing the MART-1 antigen
expressed on melanoma tumors and in vitro antitumor
immunity of regenerated MART-1 iPSC-derived T cells [10].
Nishimura et al. showed generation of iPSCs from HIV-
1-epitope specific clone of CD8+ T cells and regeneration
of functional antigen-specific T cells with capacity of pro-
ducing cytokine and cytolytic activity [9]. Themeli et al.
provided another insight into whether this approach can be
used in combination with chimeric antigen receptor (CAR)
technology by showing that genetically engineered T cell-
derived iPSCs to express a CAR specific to the CD19 antigen
can differentiate into CAR-expressing T cells which have
antitumor reactivity against CD19+ lymphoma in vitro and in
vivo [13].
Potential advantage of reprogramming and regeneration
of TILs would be to obtain polyclonal antitumor T cells tar-
geting heterogeneous populations of solid tumors for cancer
immunotherapy. Recent advances in sequencing analyses of
solid malignancies have identified significant heterogeneity
between tumors as well as within an individual tumor, which
can contribute to treatment failure and drug resistance [43–
46]. Our ultimate goal is to differentiate TIL-iPSCs with
a wide variety of TCR gene rearrangement sequences into
T cells and determine their antitumor reactivity against
heterogeneous tumor cell populations. Of note, this strategy
can also be used not only for the known tumor antigens such
as CD19 or MART-1 but also for unknown tumor antigens
once antitumor reactivity of each TIL-iPSC-derived T cell is
identified.
This strategy has some limitations in addition to the
costs and labor intensity of generating TIL-iPSCs from each
patient. It takes significant amount of time to expand TILs,
generate iPSCs, differentiate iPSCs to T cells, and identify
their tumor specificity. One possible way to utilize this
approachwould be to identify theTIL-iPSCs that differentiate
into tumor-specific T cells and store the TIL-iPSCs for
other patients with cancers expressing the appropriate tumor
antigen(s) andHLAhaplotypes, which has been described for
virus-specific T cells [47, 48] or pluripotent stem cells [49–
52]. These iPSCs bearing rearranged TCR of known antigen
specificity can differentiate into tumor-specific T cells in vivo
to promote cancer immunosurveillance or in vitro to generate
an infinite number of phenotypically defined, functional, and
expandable polyclonal T cells for adoptive T cell therapy
[12, 13].
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